{"url_path":"/sec/dmiiu/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2040475/0001213900-26-056651-index.html","accession_number":"0001213900-26-056651","cik":"0002040475","ticker":"DMII","issuer_name":"Drugs Made In America Acquisition II Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2040475/0001213900-26-056651-index.html","primary_entity_key":"0002040475","primary_entity_name":"Drugs Made In America Acquisition II Corp."},"word_count":46,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n \n\n \n(a)\nNone.\n\n \n\n  (b) None.\n\n     \n\n  (c) During the quarter ended March 31, 2026, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading agreement” or a “non-Rule 10b5-1 trading agreement” (in each case defined in Item 408 of Regulation S-K)."}